After Losing Over $16 Billion Of Market Capitalization Edwards Lifesciences (EW) Faces Investor Class Action – Hagens Berman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
October 28, 2024 8:19 AM EDTBernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.
The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More
BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 25, 2024 5:22 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).
The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More
